Trial site
Mount Vernon Cancer Centre
Northwood, Middlesex HA6 2RN, United KingdomNot linked to an institution yet
- 17running trials
- 9closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 24 trials
- Phase 2/32 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Recruiting9 trials
- Active, not recruiting8 trials
- Completed8 trials
- Terminated1 trial
- Lead sponsor
- Amgen3 trials
- Janssen Research & Development, LLC3 trials
- EMD Serono Research & Development Institute, Inc.2 trials
- AVEO Pharmaceuticals, Inc.1 trial
- Cambridge University Hospitals NHS Foundation Trust1 trial
- and 16 more
Running trials
Active, not recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
In Vivo Dosimetry for Brachytherapy Study
NCT06863090· East and North Hertfordshire NHS Trust· Source
Contact: Rishma Bhatti
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Personalized Medicine for Advanced Biliary Cancer Patients
NCT05615818· Phase 3· UNICANCER· Source
Contact: Vasiliki MICHALAREA, MD
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· Phase 3· Amgen· Source
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source
Contact: Study Director - Inhibrx
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· Phase 3· Amgen· Source
Active, not recruiting
A Prospective Natural History Study in Uveal Melanoma
NCT04588662· Columbia University· Source
Active, not recruiting
Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus
NCT04046133· Phase 1· Cardiff University· Source
Active, not recruiting
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247· OncoHost Ltd.· Source
Active, not recruiting
Avelumab Program Rollover Study
NCT03815643· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629· Prostate Cancer Clinical Trials Consortium· Source
Contact: Anand Sharma, MD
Recruiting
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03150576· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source
Contact: Stephanie Sutherland (principal investigator)
Active, not recruiting
Study of Tumour Focused Radiotherapy for Bladder Cancer
NCT02447549· Phase 2· Institute of Cancer Research, United Kingdom· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
NCT05198934· Phase 3· Amgen· Source
Completed
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT04987203· Phase 3· AVEO Pharmaceuticals, Inc.· Source
Terminated
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556· Phase 1/2· Eisai Inc.· Source
Completed
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source
Completed
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
NCT03648489· Phase 2· Imperial College London· Source
Completed
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT03371017· Phase 3· Hoffmann-La Roche· Source
Completed
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
NCT03070392· Phase 2· Immunocore Ltd· Source
Completed
Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
NCT03117933· Phase 2· University of Oxford· Source
Report an error